E
Calliditas Therapeutics AB (publ) CALT
NASDAQ
Recommendation
Prev Close
Volume
--
Avg Vol (90D)
Market Cap
Dividend & Yield
--
52-Week Range
P/E (TTM)
--
EPS (TTM)

06/30/2024 03/31/2024 12/31/2023 09/30/2023 06/30/2023
Net Income 81.25% -1,270.89% 88.91% -78.37% 51.34%
Total Depreciation and Amortization -- -- -- -- --
Total Amortization of Deferred Charges -- -- -- -- --
Total Other Non-Cash Items 106.28% -33.41% 17.37% 306.56% -220.05%
Change in Net Operating Assets -331.26% 149.56% -147.50% 218.23% 20.93%
Cash from Operations 96.55% -987.49% 137.13% 62.64% 30.23%
Capital Expenditure -- -- -- -- --
Sale of Property, Plant, and Equipment -- -- -- -- --
Cash Acquisitions -- -- -- -- --
Divestitures -- -- -- -- --
Other Investing Activities 97.44% -137.83% 242.96% -581.63% 63.89%
Cash from Investing 97.44% -67.66% 67.74% -581.63% 63.89%
Total Debt Issued -- -- -- -- --
Total Debt Repaid 25.74% 99.25% -25,098.79% 4.21% -1.55%
Issuance of Common Stock -- -- -- -- --
Repurchase of Common Stock -- -- -- -- --
Issuance of Preferred Stock -- -- -- -- --
Repurchase of Preferred Stock -- -- -- -- --
Total Dividends Paid -- -- -- -- --
Other Financing Activities -- -- -- -- --
Cash from Financing 28.06% -102.68% 7,436.85% 6.70% -0.81%
Foreign Exchange rate Adjustments -104.07% 207.03% -562.87% -131.98% 739.63%
Miscellaneous Cash Flow Adjustments -- -- -- -- -200.00%
Net Change in Cash 92.24% -189.46% 339.45% 47.61% 37.87%
Weiss Ratings